Author Login

Correspondence to Author: Dukundane Allain Tresor, Ndayisabye Jean De La Croix. 

Ndayisabye Jean De La Croix , Biomedical Laboratory Practitioners, Rwanda, East Africa, Gatsata

DOI: 10.52338/tjov.2025.4291

Abstract:

The study conducted in Rwanda where it investigated the mutations in the HIV-1 reverse transcriptase (RT) gene that lead to resistance to two widely used drugs, lamivudine (3TC) and emtricitabine (FTC). These two nucleoside reverse transcriptase inhibitors (NRTIs) are integral to the antiretroviral therapy (ART) regimen for HIV patients. The study aims to identify specific mutations that confer resistance, explore the cross-resistance between 3TC and FTC, and assess how these mutations impact the effectiveness of treatment. Zhang’s findings underscore the significance of the M184V/I mutations as the primary cause of drug resistance and crossresistance between both drugs. The study also touches upon the viral fitness costs and implications for treatment regimens.
Keywords: HIV-1, Reverse Transcriptase, Mutations, Resistance, Lamivudine, Emtricitabine, ART, M184V, Cross-resistance.

Citation:

Dr.Ndayisabye Jean De La Croix, Mutations In The Hiv-1 Reverse Transcriptase Gene Associated With Resistance To Lamivudine And Emtricitabine. The Journal of Virology 2025.